---

Highlights of May 2019

1. Glenmark Therapeutics inks pact with Otonomy to promote Otiprio in US.
2. Lupin, Aptissen sign pact to sell Osteoarthritis injection in Canada.
3. Pfizer to acquire Therachon for US$810 Million.
4. Perrigo buys oral healthcare firm Ranir Global for US$750 Million.
5. Boston Scientific snatches up spine-spacer developer Vertiflex in US$465 Million deal.
6. Lundbeck to acquire Abide Therapeutics for US$250 Million.
7. Amgen to buy Scandinavian Nuevolution AB for US$166.8 Million to boost its position in drug discovery.
8. Vertex pays Kymera US$70 Million upfront to discover protein degradation drugs.
9. OncoSec buys rights from Gaeta Therapeutics.
10. Evotec to acquire Gates Foundation-backed Just Biotherapeutics.
11. Takeda teams up with Frazier Healthcare for GI biotech launch.
12. China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering.

Updates at Aagami: 

• Aagami completed BIO International Convention 2019 with 40+ one-one-one strategic and fruitful meetings.
• Also, Aagami generated 45+ meetings for its clients.
• New Client Win: Israeli BioPharma Company chooses Aagami for partnering of their ‘Novel Treatment for Non-Surgical Removal of Skin Lesions’ (incl. corns, warts, skin tags) already on the OTC market (EU and selected additional territories). Aagami to support out-licensing in India and selective other regions.